Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Novartis, Lonza strengthen biosimilars push with MS, arthritis drug deals

      Novartis, Lonza strengthen biosimilars push with MS, arthritis drug deals

      Medical Dialogues Bureau3 Sept 2019 9:30 AM IST
      Novartis's Sandoz generics unit, among the biggest biosimilars makers, on Tuesday, agreed to license from Poland's Polpharma Biologics a version of...
      Roche Xofluza shows promise in reducing risk of developing flu by 86pc

      Roche Xofluza shows promise in reducing risk of developing flu by 86pc

      Medical Dialogues Bureau3 Sept 2019 9:05 AM IST
      "Xofluza is the first and only one-dose oral medicine approved to treat flu in otherwise healthy patients, and the first new flu medicine with a novel...
      China expansion of drug bulk-buy programme puts pressure on pharma companies

      China expansion of drug bulk-buy programme puts pressure on pharma companies

      Medical Dialogues Bureau3 Sept 2019 9:00 AM IST
      The programme rolled out last year saw 11 Chinese cities, including Beijing and Shanghai, band together behind a tender process to bulk-buy 25 types...
      Sanofi revival depends on outsider with nose for big drugs: Report

      Sanofi revival depends on outsider with nose for big drugs: Report

      Medical Dialogues Bureau3 Sept 2019 8:58 AM IST
      Defining Sanofi's ambitions in the cutting-edge field of gene therapies and figuring out whether to hold on to consumer health brands are among other...
      Fund Diversion Case: SEBI restricts Transgene Biotek, 6 others from securities market

      Fund Diversion Case: SEBI restricts Transgene Biotek, 6 others from securities market

      Medical Dialogues Bureau2 Sept 2019 10:00 AM IST
      Besides, Transgene will continue the measures to recall the outstanding amount of USD 38.5 million and bring the money back into its bank account in...
      Amgen challenges Alexion Pharma blood disorder treatment Soliris in US patent court

      Amgen challenges Alexion Pharma blood disorder treatment Soliris in US patent court

      Medical Dialogues Bureau2 Sept 2019 9:30 AM IST
      The IPR is seeking to invalidate new patents covering the composition of the main ingredient of Soliris, eculizumab, its formulation, and its use to...
      Kyowa Kirin gets USFDA approval for Nourianz tablets to treat adults with Parkinsons disease

      Kyowa Kirin gets USFDA approval for Nourianz tablets to treat adults with Parkinsons disease

      Medical Dialogues Bureau2 Sept 2019 9:00 AM IST
      New Delhi: Kyowa Kirin, Inc. recently won the U.S. Food and Drug Administration approval for Nourianz (istradefylline) tablets as an add-on treatment...
      Violation of Market Norms: SEBI imposes Rs 1.15 crore fine on Pharma Company

      Violation of Market Norms: SEBI imposes Rs 1.15 crore fine on Pharma Company

      Medical Dialogues Bureau1 Sept 2019 11:00 AM IST
      During the investigation, SEBI revealed that the loan paid by Vintage was secured by pledge agreement between Syncom and EURAM Bank.New Delhi: Markets...
      Sandoz recalls Losartan Potassium, Ezetimibe drug bottles in US over packaging issue

      Sandoz recalls Losartan Potassium, Ezetimibe drug bottles in US over packaging issue

      Medical Dialogues Bureau1 Sept 2019 9:37 AM IST
      New Delhi: Sandoz Inc. recently announced a voluntary recall and corrective action notice for particular lots of Losartan Potassium and Ezetimibe...
      USFDA expands investigation on generic drug impurities in US

      USFDA expands investigation on generic drug impurities in US

      Medical Dialogues Bureau1 Sept 2019 9:35 AM IST
      Since last summer, the USFDA has been conducting a major investigation to address the presence of certain impurities that could cause cancer in ARBs...
      AstraZeneca lupus drug Anifrolumab shows encouraging sign in final stage

      AstraZeneca lupus drug Anifrolumab shows encouraging sign in final stage

      Medical Dialogues Bureau1 Sept 2019 9:30 AM IST
      AstraZeneca said Anifrolumab under the TULIP 2 program helped patients with systemic lupus erythematosus, commonly known as SLE.U.S: AstraZeneca Plc...
      GSK Pharma sells 60 acres land in Thane to Oberoi Realty for Rs 890 crore

      GSK Pharma sells 60 acres land in Thane to Oberoi Realty for Rs 890 crore

      Medical Dialogues Bureau31 Aug 2019 12:54 PM IST
      Mumbai: Glaxo Smith Kline Pharmaceuticals (GSK) has divested around 60 acres of its lands at Thane in favour of Oberoi Realty for nearly Rs 890 crore...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok